ReviewBioMed research international2023
Recent Approaches for Downplaying Antibiotic Resistance: Molecular Mechanisms.
Review in BioMed research international, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 59 citations in OpenAlex.
- Chemical Optimization of Temporin A-L Peptides: From Native Isoforms to Enhanced Antimicrobial Analogs.ChemMedChem · 2026Review
- Antimicrobial Peptides as Antibiotic Adjuvants: Overcoming Resistance through Multifaceted Mechanisms.Probiotics and antimicrobial proteins · 2026Article
- Mechanisms ofMedicina (Kaunas, Lithuania) · 2026Review
- Emerging trends and structure-activity insights of Schiff base-lanthanide complexes as antibacterial agents.RSC advances · 2026Review
- Assessment of MgO, ZnO, chitosan hydroxyapatite and silver hydroxyapatite nanoparticles against carbapenem-resistant Gram-negative Egyptian clinical isolates: a combined in-silico and in-vitro study.BMC microbiology · 2025Article
- Molecular characterization of multidrug-resistant Escherichia coli in the Greater Accra Region, Ghana: a 'One Health' approach.One health outlook · 2025Article
- What Are the Drivers Triggering Antimicrobial Resistance Emergence and Spread? Outlook from a One Health Perspective.Antibiotics (Basel, Switzerland) · 2025Review
- Artificial intelligence in drug resistance management.3 Biotech · 2025Review
- Dose response effects of dietary clove and peppermint oils on the growth performance, physio-metabolic response, feed utilization, immunity, and organ histology in African catfish (clarias gariepinus).Veterinary research communications · 2025Article
- Menadione as Antibiotic Adjuvant AgainstAntibiotics (Basel, Switzerland) · 2025Article
- Therapeutic efficacy ofFrontiers in nutrition · 2025Review
- Chemically diverse antimicrobial peptides induce hyperpolarization of the E. coli membrane.Communications biology · 2024Article
- A multifunctional injectable, self-healing, and adhesive hydrogel-based wound dressing stimulated diabetic wound healing with combined reactive oxygen species scavenging, hyperglycemia reducing, and bacteria-killing abilities.Journal of nanobiotechnology · 2024Article
- Bioinformatics-Driven mRNA-Based Vaccine Design for Controlling Tinea Cruris Induced byPharmaceutics · 2024Article
- Antimicrobial Resistance Levels of Non-Tuberculous Bacteria Isolates from Sputum of TB Patients in Ghana.Infection and drug resistance · 2024Article
- Characterization of a Novel Sequence Type (ST) 6758Infection and drug resistance · 2024Article
- In Silico and In Vitro Identification of 1,8-Dihydroxy-4,5-dinitroanthraquinone as a New Antibacterial Agent againstMolecules (Basel, Switzerland) · 2023Article
- Structural Study of a New MbtI-Inhibitor Complex: Towards an Optimized Model for Structure-Based Drug Discovery.Pharmaceuticals (Basel, Switzerland) · 2023Article
- An Update Review of Approaches to Multiple Action-Based Antibacterials.Antibiotics (Basel, Switzerland) · 2023Review
- Antibiotic adjuvants: synergistic tool to combat multi-drug resistant pathogens.Frontiers in cellular and infection microbiology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 6 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antimicrobial resistance (AMR) is a ubiquitous public health menace. AMR emergence causes complications in treating infections contributing to an upsurge in the mortality rate. The epidemic of AMR in sync with a high utilization rate of antimicrobial drugs signifies an alarming situation for the fleet recovery of both animals and humans. The emergence of resistant species calls for new treatments and therapeutics. Current records propose that health drug dependency, veterinary medicine, agricultural application, and vaccination reluctance are the primary etymology of AMR gene emergence and spread. Recently, several encouraging avenues have been presented to contest resistance, such as antivirulent therapy, passive immunization, antimicrobial peptides, vaccines, phage therapy, and botanical and liposomal nanoparticles. Most of these therapies are used as cutting-edge methodologies to downplay antibacterial drugs to subdue the resistance pressure, which is a featured motive of discussion in this review article. AMR can fade away through the potential use of current cutting-edge therapeutics, advancement in antimicrobial susceptibility testing, new diagnostic testing, prompt clinical response, and probing of new pharmacodynamic properties of antimicrobials. It also needs to promote future research on contemporary methods to maintain host homeostasis after infections caused by AMR. Referable to the microbial ability to break resistance, there is a great ultimatum for using not only appropriate and advanced antimicrobial drugs but also other neoteric diverse cutting-edge therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.